Fyra viktiga och nyskapande kliniska studier på nya antipsykotika slutförs i år.
Brilaroxazin, som är en dopamin-serotonin stabiliserare, evenamid (alternativ till Clozapine), ulotaront (TAAR1 och serotonin 5-HT1A receptor agonist) och pimavanserin (mot negativa symptom).
Läs mer hos Clinical Trials Arena.
https://www.lifescienceleader.com/doc/reviva-pharma-s-novel-funding-approach-in-schizophrenia-0001
Den verkar via D2/3/4 and 5-HT1A/2A receptorer som en partiell agonist och blockerar 5-HT2B/7 receptorer. Den kontrollerar cytokiner som kan driva på sjukdomen.
https://www.hcplive.com/view/phase-3-data-on-brilaroxazine-for-schizophrenia-with-larry-ereshefsky-pharmd
https://www.psychiatrictimes.com/view/positive-topline-results-reported-for-phase-3-clinical-trial-evaluating-schizophrenia-treatment
https://www.businesswire.com/news/home/20231009265107/en/Newron-TRS-Study-6-Months%E2%80%99-Results-Evenamide-Substantially-Improves-Patients-to-an-Extent-That-They-No-Longer-Meet-Protocol-Entry-Criteria
https://www.fiercebiotech.com/biotech/sumitomo-otsuka-schizophrenia-drug-flunks-pair-phase-3-trials-amid-high-placebo-response
https://news.sunovion.com/press-releases/press-releases-details/2023/Sunovion-and-Otsuka-Initiate-Clinical-Development-of-Ulotaront-for-the-Treatment-of-Generalized-Anxiety-Disorder/default.aspx